Ibrutinib Inhibits Platelet Integrin αiIbβ3 Outside-In Signaling and Thrombus Stability but Not Adhesion to Collagen

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 11, 2015, Pages 2326-2335

  Bye, Alexander P ^a   Unsworth, Amanda J ^a   Vaiyapuri, Sakthivel ^a   Stainer, Alexander R ^a   Fry, Michael J ^a   Gibbins, Jonathan M ^a  

^a UNIVERSITY OF READING   (United Kingdom)

Author keywords

collagen; fibrinogen; hemostasis; ligands; Waldenstrom macroglobulinemia

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ALPHA INTEGRIN; CANGRELOR; COLLAGEN; COLLAGEN RELATED PEPTIDE; DASATINIB; FIBRINOGEN; IBRUTINIB; INTEGRIN ALPHA IIB BETA 3; PEPTIDE; PHOSPHOLIPASE C GAMMA2; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ADENOSINE PHOSPHATE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; FIBRINOGEN RECEPTOR; PROTEIN KINASE INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ARTICLE; BLOOD CLOT RETRACTION; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HUMAN; IC50; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBUS; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; CALCIUM SIGNALING; CHEMICALLY INDUCED; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; HEMOSTASIS; METABOLISM; RISK FACTOR; THROMBOCYTE; TIME;

ADENOSINE MONOPHOSPHATE; BLOOD PLATELETS; CALCIUM SIGNALING; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOGEN; HEMORRHAGE; HEMOSTASIS; HUMANS; PLATELET ADHESIVENESS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; PYRAZOLES; PYRIMIDINES; RISK FACTORS; TIME FACTORS;

EID: 84945476505     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.306130     Document Type: Article

References (26)

1. Byrd JC, Furman RR, Coutre SE, Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013 369 32 42. doi: 10.1056/NEJMoa1215637
2. Rushworth SA, MacEwan DJ, Bowles KM, Ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013 369 1277 1278. doi: 10.1056/NEJMc1309710#SA2
3. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, Cole-Sinclair M, Reynolds J, Filshie R, Schischka S, Khot A, Sandhu S, Keating MJ, Nandurkar H, Tam CS, Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2015 29 783 787. doi: 10.1038/leu.2014.247
4. Levade M, David E, Garcia C, Laurent PA, Cadot S, Michallet AS, Bordet JC, Tam C, Sié P, Ysebaert L, Payrastre B, Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions. Blood 2014 124 3991 3995. doi: 10.1182/blood-2014-06-583294
5. Quek LS, Bolen J, Watson SP, A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen. Curr Biol 1998 8 1137 1140
6. Atkinson BT, Ellmeier W, Watson SP, Tec regulates platelet activation by GPVI in the absence of Btk. Blood 2003 102 3592 3599. doi: 10.1182/blood-2003-04-1142
7. Poenie M, Alteration of intracellular Fura-2 fluorescence by viscosity: a simple correction. Cell Calcium 1990 11 85 91
8. Nieswandt B, Watson SP, Platelet-collagen interaction: is GPVI the central receptor? Blood 2003 102 449 461. doi: 10.1182/blood-2002-12-3882
9. Liu J, Fitzgerald ME, Berndt MC, Jackson CW, Gartner TK, Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivo. Blood 2006 108 2596 2603. doi: 10.1182/blood-2006-01-011817
10. Soriani A, Moran B, de Virgilio M, Kawakami T, Altman A, Lowell C, Eto K, Shattil SJ, A role for PKCtheta in outside-in alpha(IIb)beta3 signaling. J Thromb Haemost 2006 4 648 655. doi: 10.1111/j.1538-7836.2006.01806.x
11. Law DA, DeGuzman FR, Heiser P, Ministri-Madrid K, Killeen N, Phillips DR, Integrin cytoplasmic tyrosine motif is required for outside-in alphaIIbbeta3 signalling and platelet function. Nature 1999 401 808 811. doi: 10.1038/44599
12. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, Kolibaba KS, Furman RR, Rodriguez S, Chang BY, Sukbuntherng J, Izumi R, Hamdy A, Hedrick E, Fowler NH, Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013 31 88 94. doi: 10.1200/JCO.2012.42.7906
13. Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ, The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 2010 107 13075 13080. doi: 10.1073/pnas.1004594107
14. Inoue O, Suzuki-Inoue K, Dean WL, Frampton J, Watson SP, Integrin alpha2beta1 mediates outside-in regulation of platelet spreading on collagen through activation of Src kinases and PLCgamma2. J Cell Biol 2003 160 769 780. doi: 10.1083/jcb.200208043
15. Sakurai Y, Fitch-Tewfik JL, Qiu Y, Ahn B, Myers DR, Tran R, Fay ME, Ding L, Spearman PW, Michelson AD, Flaumenhaft R, Lam WA, Platelet geometry sensing spatially regulates α-granule secretion to enable matrix self-deposition. Blood 2015 126 531 538. doi: 10.1182/blood-2014-11-607614
16. Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J, Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 2009 115 2482 2490. doi: 10.1002/cncr.24257
17. Heemskerk JW, Willems GM, Rook MB, Sage SO, Ragged spiking of free calcium in ADP-stimulated human platelets: regulation of puff-like calcium signals in vitro and ex vivo. J Physiol 2001 535 pt 3 625 635
18. Harrison P, Mackie I, Mumford A, Briggs C, Liesner R, Winter M, Machin S, British Committee for Standards in Haematology Guidelines for the laboratory investigation of heritable disorders of platelet function. Br J Haematol 2011 155 30 44. doi: 10.1111/j.1365-2141.2011.08793.x
19. de Witt SM, Swieringa F, Cavill R, Identification of platelet function defects by multi-parameter assessment of thrombus formation. Nat Commun 2014 5 4257. doi: 10.1038/ncomms5257
20. Oda A, Ikeda Y, Ochs HD, Druker BJ, Ozaki K, Handa M, Ariga T, Sakiyama Y, Witte ON, Wahl MI, Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking. Blood 2000 95 1663 1670
21. Arthur JF, Dunkley S, Andrews RK, Platelet glycoprotein VI-related clinical defects. Br J Haematol 2007 139 363 372. doi: 10.1111/j.1365-2141.2007.06799.x
22. Moroi M, Jung SM, Okuma M, Shinmyozu K, A patient with platelets deficient in glycoprotein VI that lack both collagen-induced aggregation and adhesion. J Clin Invest 1989 84 1440 1445. doi: 10.1172/JCI114318
23. Takahashi H, Moroi M, Antibody against platelet membrane glycoprotein VI in a patient with systemic lupus erythematosus. Am J Hematol 2001 67 262 267. doi: 10.1002/ajh.1128
24. Kojima H, Moroi M, Jung SM, Goto S, Tamura N, Kozuma Y, Suzukawa K, Nagasawa T, Characterization of a patient with glycoprotein (GP) VI deficiency possessing neither anti-GPVI autoantibody nor genetic aberration. J Thromb Haemost 2006 4 2433 2442. doi: 10.1111/j.1538-7836.2006.02173.x
25. Marjoram RJ, Voss B, Pan Y, Dickeson SK, Zutter MM, Hamm HE, Santoro SA, Suboptimal activation of protease-activated receptors enhances alpha2beta1 integrin-mediated platelet adhesion to collagen. J Biol Chem 2009 284 34640 34647. doi: 10.1074/jbc.M109.020990
26. Marjoram RJ, Li Z, He L, Tollefsen DM, Kunicki TJ, Dickeson SK, Santoro SA, Zutter MM, α2β1 integrin, GPVI receptor, and common FcRγ chain on mouse platelets mediate distinct responses to collagen in models of thrombosis. PLoS One 2014 9 e114035. doi: 10.1371/journal.pone.0114035